Abstract 1564P
Background
With over 2 million cases diagnosed annually, breast cancer is a leading cause of cancer-related disability and mortality worldwide. Despite global efforts to implement screening programs, uptake rates vary widely across settings due to socioeconomic factors and accessibility challenges. In 2022 in Flanders (Belgium), breast cancer screening participation in municipalities with income below the poverty line was 15% lower than average.
Methods
To tackle the limited participation of low-SES women in the breast cancer screening program in Flanders, a culturally sensitive approach was used to realize a tailored reminder letter.
33 women (of which 29 non-native Dutch speakers) aged 50-69 with low-SES were identified with the assistance of community organizations to conduct Focus Group Discussions (FGDs). Through a series of 4 FGDs and 3 rounds of Delphi-consultations involving sector experts, valuable insights were gathered.
Results
Analysis of the standard invitation letter employed in the program revealed several challenges related to readability and comprehension. These included the excessive length of the text, the use of complex vocabulary and grammar beyond an A2 level, the inclusion of contextual sentences unrelated to the mammography appointment (“We do it. And what do you do?”), and the use of generic visuals (eg. a picture of women).
At the same time, simplifying the vocabulary to A1-A2 levels (“cancer”, “doctor”, “appointment”, “check”, “free”), employing straightforward sentence structures, and incorporating relevant visuals (e.g. image of a mammography machine) enhanced understandability and fostered interest in breast cancer prevention. Additionally, utilizing a color palette associated with breast cancer and featuring logos of local authorities instilled a sense of credibility and trustworthiness.
Conclusions
Based on feedback from sector experts and insights from the FGDs, a revised reminder letter was developed. The final communication was concise and included essential details such as time and place for screening, as well as a QR code providing translation into 12 languages.
To assess its efficacy in increasing participation rates, a RCT with 3,430 participants per arm is currently being conducted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Stichting tegen Kanker.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10